10x Genomics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shareholders voted on company leadership; Serge Saxonov, Benjamin Hindson, and John Stuelpnagel will guide the company through 2029.
Quarterly earnings show how the company performed in early 2026; helps investors track progress over time.
Auditors check that financial reports are honest and accurate; shareholders approved the choice with 197.7 million votes.
Annual earnings show total company performance for the whole year; important baseline for comparing future quarters.
Investors voted to support how much executives earn; 176.7 million shares voted in favor of the compensation package.
Stocky reads 10x Genomics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
10x Genomics, Inc.'s most recent tracked filing was a 8-K on 8 Jun 2026: Stockholders elect three directors for three-year terms.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.